| scholarly article | Q13442814 |
| P50 | author | Gavin P. Robertson | Q55873679 |
| Arati Sharma | Q63934950 | ||
| Gregory R Kardos | Q87832569 | ||
| Raghavendra Gowda | Q88023903 | ||
| P2093 | author name string | Sanjay Singh | |
| P2860 | cites work | Regulation of inflammation in cancer by eicosanoids | Q24564308 |
| Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA | Q24675575 | ||
| Pathways and therapeutic targets in melanoma | Q26865736 | ||
| Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer | Q27330395 | ||
| Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells | Q28195446 | ||
| Minireview: Cyclin D1: normal and abnormal functions | Q28279069 | ||
| Nanocarriers as an emerging platform for cancer therapy | Q29616699 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo | Q30475089 | ||
| Targeting Akt3 signaling in malignant melanoma using isoselenocyanates | Q33408109 | ||
| Resistance to Raf inhibition in cancer | Q33651779 | ||
| Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy | Q33859472 | ||
| Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor | Q33882627 | ||
| Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway | Q34291456 | ||
| Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. | Q34413011 | ||
| Circumventing tumor resistance to chemotherapy by nanotechnology | Q34618357 | ||
| Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs | Q34743086 | ||
| Targeting multiple key signaling pathways in melanoma using leelamine. | Q35136450 | ||
| Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. | Q35225907 | ||
| Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. | Q35747332 | ||
| Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells via the Inhibition of STAT3 Signaling and Down-regulation of Inflammatory Cytokine Expressions | Q35755120 | ||
| Activation of stat3 in human melanoma promotes brain metastasis | Q48616814 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. | Q50913842 | ||
| NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. | Q54642733 | ||
| How melanomas bypass new therapy | Q59043395 | ||
| Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains | Q72014136 | ||
| Observations on the pharmacology and hemolytic activity of dimethyl sulfoxide | Q72657553 | ||
| Activity of paclitaxel liposome formulations against human ovarian tumor xenografts | Q73209085 | ||
| Loss of PTEN promotes tumor development in malignant melanoma | Q73469277 | ||
| UV/Vis spectra and solubility of some naphthoquinones, and the extraction behavior of plumbagin from Plumbago scandens roots in supercritical CO2 | Q79768820 | ||
| Mechanisms of drug combinations: interaction and network perspectives | Q83265745 | ||
| MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells | Q35784718 | ||
| Targeting sphingosine kinase-1 to inhibit melanoma. | Q35789935 | ||
| The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. | Q35873359 | ||
| The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. | Q35911227 | ||
| Targeting STAT3 affects melanoma on multiple fronts | Q36178382 | ||
| Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways | Q36466176 | ||
| Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma | Q36536476 | ||
| Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma | Q36750123 | ||
| Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy | Q36952188 | ||
| STAT3 as a target for inducing apoptosis in solid and hematological tumors | Q37029162 | ||
| Is B-Raf a good therapeutic target for melanoma and other malignancies? | Q37048982 | ||
| The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment | Q37366259 | ||
| Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism | Q37370608 | ||
| COX-2 as a target for cancer chemotherapy | Q37761270 | ||
| The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs | Q37990748 | ||
| Discovery of small molecule cancer drugs: successes, challenges and opportunities | Q37996113 | ||
| From genes to drugs: targeted strategies for melanoma | Q37999967 | ||
| Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy | Q38015042 | ||
| Nanoparticle-assisted combination therapies for effective cancer treatment. | Q38027852 | ||
| Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations". | Q38098816 | ||
| Nanomedicine applied to translational oncology: A future perspective on cancer treatment | Q38586904 | ||
| Survival of patients with advanced metastatic melanoma: The impact of novel therapies | Q38680472 | ||
| Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy | Q38716666 | ||
| Plumbagin shows anti-cancer activity in human breast cancer cells by the upregulation of p53 and p21 and suppression of G1 cell cycle regulators | Q38780551 | ||
| Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas | Q39205805 | ||
| Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model | Q39219294 | ||
| Genotype-selective combination therapies for melanoma identified by high-throughput drug screening | Q39226193 | ||
| Selenium-containing histone deacetylase inhibitors for melanoma management | Q39336516 | ||
| MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. | Q39417513 | ||
| Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. | Q39694546 | ||
| Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. | Q39899988 | ||
| Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. | Q39977960 | ||
| Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers | Q40185493 | ||
| ET-18-O-CH3-induced apoptosis is causally linked to COX-2 upregulation in H-ras transformed human breast epithelial cells | Q40357493 | ||
| Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells | Q40516675 | ||
| Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression | Q40882239 | ||
| COX-2 in cancer--a player that's defining the rules | Q43963620 | ||
| COX-2 expression in malignant melanoma: a novel prognostic marker? | Q47833354 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 440-452 | |
| P577 | publication date | 2016-12-21 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma | |
| P478 | volume | 16 |
| Q92744195 | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis |
| Q88795679 | Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review |
| Q92373586 | Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing |
| Q90723914 | Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma |
| Q48155250 | Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. |
| Q33709666 | Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport |
| Q92315508 | Liposome Delivery of Natural STAT3 Inhibitors for the Treatment of Cancer |
| Q93379379 | Molecular simulation and in vitro evaluation of chitosan nanoparticles as drug delivery systems for the controlled release of anticancer drug cytarabine against solid tumours |
| Q50113740 | Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment |
| Q90611684 | Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications |
| Q64062363 | Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment |
Search more.